Interleukin-10 inhibition of the progression of established collagen-induced arthritis.
OBJECTIVE
Interleukin-10 (IL-10) is a potent inhibitor of the proinflammatory cytokines, including tumor necrosis factor alpha and IL-1, which are considered important in the pathogenesis of rheumatoid arthritis (RA). The study was undertaken to establish whether IL-10 can ameliorate arthritis in the collagen-induced arthritis (CIA) model of RA.


METHODS
DBA/1 mice were immunized with bovine type II collagen in adjuvant, and treated daily after disease onset with recombinant murine IL-10 or with saline as a control. Mice were monitored for paw swelling and clinical score. Histologic analysis was also performed.


RESULTS
IL-10 treatment of established CIA inhibited paw swelling (P < 0.0001), as well as disease progression as defined by clinical score (P < 0.0002). Cartilage destruction, as assessed histologically, was reduced in IL-10-treated mice compared with controls (P < 0.01).


CONCLUSIONS
IL-10 suppresses established CIA, probably by inhibiting proinflammatory cytokine production. Our results, taken together with previously reported findings, indicate a potential therapeutic role for IL-10 in RA.
Walmsley
M
M
Kennedy Institute of Rheumatology, London, England.
Katsikis
P D
PD
Abney
E
E
Parry
S
S
Williams
R O
RO
Maini
R N
RN
Feldmann
M
M
D000818:Animals; D001169:Arthritis, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D002417:Cattle; D003094:Collagen / Q000009:adverse effects; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D004338:Drug Combinations; D016753:Interleukin-10 / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D004338:Drug Combinations; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D003094:Collagen